Drug Patents Expiring in 2030
1. Abilify Mycite Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(5 years from now) | |
| US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(6 years from now) | |
| US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(6 years from now) | |
| US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(6 years from now) | |
| US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(6 years from now) | |
| US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(6 years from now) | |
| US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(6 years from now) | |
| US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
2. Acetaminophen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741959 | FRESENIUS KABI USA | Paracetamol for parenteral administration |
Apr, 2030
(5 years from now) | |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 28 October, 2015
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
ACETAMINOPHEN family patents
3. Acuvue Theravision With Ketotifen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9962376 | JOHNSON JOHNSON VISN | Methods and ophthalmic devices used in the treatment of ocular allergies |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS;OPHTHALMIC
ACUVUE THERAVISION WITH KETOTIFEN family patents
4. Adlyxin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8915888 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Jun, 2030
(6 years from now) | |
| US9981013 | SANOFI-AVENTIS US | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
Aug, 2030
(6 years from now) | |
| US10028910 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
Nov, 2030
(6 years from now) | |
| US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(6 years from now) | |
| US8475414 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(6 years from now) | |
| US9308329 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector; Improvement of glycemic control in type 2 diabetes patients by administering a starting dose of 10 mcg fo...
Dosage: SOLUTION;SUBCUTANEOUS
ADLYXIN family patents
5. Afrezza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9511198 | MANNKIND | Dry powder inhaler and system for drug delivery |
Feb, 2030
(5 years from now) | |
| US8485180 | MANNKIND | Dry powder drug delivery system |
Mar, 2030
(5 years from now) | |
| US8778403 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
| US8551528 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
| US8734845 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
| US10201672 | MANNKIND | Dry powder inhaler and system for drug delivery |
Aug, 2030
(6 years from now) | |
| US10500159 | MANNKIND | Apparatus and method for cryogranulating a pharmaceutical composition |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder.; Administrat...
Dosage: POWDER;INHALATION
AFREZZA family patents
6. Airsupra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 10, 2026 |
Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient
Market Authorisation Date: 10 January, 2023
Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older
Dosage: AEROSOL, METERED;INHALATION
AIRSUPRA family patents
7. Akynzeo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US11559523 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US9943515 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US8951969 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US8623826 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 10 October, 2014
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limite...
Dosage: CAPSULE;ORAL
AKYNZEO family patents
8. Akynzeo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
NCE-1 date: 19 April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
AKYNZEO family patents
9. Alecensa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9440922 | HOFFMANN-LA ROCHE | Tetracyclic compound |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-159) | Nov 06, 2024 |
| New Indication(I-756) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-105) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Nov 06, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2020 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2019
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
ALECENSA family patents
10. Amondys 45 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
| US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
| US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein prod...
Dosage: SOLUTION;INTRAVENOUS
AMONDYS 45 family patents
11. Amzeeq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10086080 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(6 years from now) | |
| US10137200 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
| US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10517882 | JOURNEY | Method for healing of an infected acne lesion without scarring |
Oct, 2030
(6 years from now) | |
| US10821187 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(6 years from now) | |
| US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
AMZEEQ family patents
12. Anjeso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11253478 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(6 years from now) | |
| US9974746 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(6 years from now) | |
| US10709713 | BAUDAX | Nanoparticulate meloxicam formulations |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
ANJESO family patents
13. Anoro Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
ANORO ELLIPTA family patents
14. Apadaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9132125 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(6 years from now) | |
| US9549923 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof |
Jul, 2030
(6 years from now) | |
| US8748413 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8828978 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(6 years from now) | |
Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 January, 2019
Treatment: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: TABLET;ORAL
APADAZ family patents
15. Apriso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8865688 | SALIX | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 31, 2011 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
APRISO family patents
16. Aptiom patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8372431 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: NA
Dosage: TABLET;ORAL
APTIOM family patents
17. Aristada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA family patents
18. Aristada Initio Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT family patents
19. Armonair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
20. Arnuity Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-290) | Mar 01, 2026 |
| New Strength(NS) | May 17, 2021 |
| New Patient Population(NPP) | May 17, 2021 |
| New Product(NP) | Aug 20, 2017 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: NA
Dosage: POWDER;INHALATION
ARNUITY ELLIPTA family patents
21. Atrovent Hfa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8474447 | BOEHRINGER INGELHEIM | Inhaler device |
Jan, 2030
(5 years from now) | |
Drugs and Companies using IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 27 November, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
ATROVENT HFA family patents
22. Aubagio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
AUBAGIO family patents
23. Auryxia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10300039 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(6 years from now) | |
| US9387191 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorus levels
Dosage: TABLET;ORAL
AURYXIA family patents
24. Avycaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
| New Patient Population(NPP) | Dec 20, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
| New Indication(I-738) | Jun 22, 2019 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 26 February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
AVYCAZ family patents
25. Besivance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(5 years from now) | |
| US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2014 |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
NCE-1 date: 28 May, 2013
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC
BESIVANCE family patents
26. Bevespi Aerosphere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9463161 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8703806 | ASTRAZENECA | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) | |
| US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US8808713 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8324266 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 25, 2019 |
Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
BEVESPI AEROSPHERE family patents
27. Bevyxxa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: NA
Dosage: CAPSULE;ORAL
BEVYXXA family patents
28. Beyaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(5 years from now) | |
| US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 24, 2013 |
| New Combination(NC) | Sep 24, 2013 |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 24 September, 2010
Treatment: Treatment of mood changes and/or anxiety as symptoms of premenstrual dysphoric disorder (pmdd) in women who choose to use an oral contraceptive as their method of contraception
Dosage: TABLET;ORAL
BEYAZ family patents
29. Braftovi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541575 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Feb, 2030
(5 years from now) | |
| USRE49556 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Feb, 2030
(5 years from now) | |
| US8501758 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US9593099 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9850230 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| Orphan Drug Exclusivity(ODE-445) | Oct 11, 2030 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| New Indication(I-826) | Apr 08, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Treatment of melanoma with a braf mutation; Treatment of melanoma; Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Braftovi is a kinase inhibitor indicate...
Dosage: CAPSULE;ORAL
BRAFTOVI family patents
30. Breo Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 13, 2026 |
| New Strength(NS) | May 13, 2026 |
| Pediatric Exclusivity(PED) | Nov 13, 2026 |
| M(M-202) | May 15, 2020 |
| New Product(NP) | May 10, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
| New Indication(I-708) | Apr 30, 2018 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: NA
Dosage: POWDER;INHALATION
BREO ELLIPTA family patents
31. Brexafemme patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188085 | SCYNEXIS | Antifungal agents |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2026 |
| New Indication(I-903) | Nov 30, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 01, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 01 June, 2030
Market Authorisation Date: 01 June, 2021
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)
Dosage: TABLET;ORAL
BREXAFEMME family patents
32. Breztri Aerosphere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8808713 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8703806 | ASTRAZENECA AB | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) | |
| US8324266 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US9415009 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US10716753 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US9463161 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2023 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 23 July, 2020
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
BREZTRI AEROSPHERE family patents
33. Brilinta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(5 years from now) | |
|
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
| New Indication(I-851) | May 28, 2023 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-714) | Sep 03, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: NA
Dosage: TABLET;ORAL
BRILINTA family patents
34. Briviact patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Treatment: NA
Dosage: TABLET;ORAL
BRIVIACT family patents
35. Bydureon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| New Patient Population(NPP) | Jul 22, 2024 |
| M(M-240) | Feb 15, 2022 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| New Product(NP) | Jan 27, 2015 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON family patents
36. Bydureon Bcise patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895033 | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| M(M-240) | Feb 15, 2022 |
| New Product(NP) | Oct 20, 2020 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON BCISE family patents
37. Bydureon Pen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8998876 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
|
US8998876 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(6 years from now) | |
|
US8721615 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| New Patient Population(NPP) | Jul 22, 2024 |
| M(M-240) | Feb 15, 2022 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| New Product(NP) | Jan 27, 2015 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON PEN family patents
38. Cabometyx patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11091439 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US8877776 | EXELIXIS INC | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11098015 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US11091440 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| New Indication(I-854) | Jan 22, 2024 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
| New Indication(I-873) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Indication(I-760) | Dec 19, 2020 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-792) | Jan 14, 2022 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy
Dosage: TABLET;ORAL
CABOMETYX family patents
39. Caldolor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9012508 | CUMBERLAND PHARMS | Administration of intravenous ibuprofen |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Nov 19, 2024 |
| New Patient Population(NPP) | May 11, 2026 |
| New Product(NP) | Jun 11, 2012 |
| New Dosing Schedule(D-152) | Nov 20, 2018 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity
Dosage: SOLUTION;INTRAVENOUS
CALDOLOR family patents
40. Cerdelga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Aug 19, 2021 |
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2019 |
| Orphan Drug Exclusivity(ODE-73) | Aug 19, 2021 |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
NCE-1 date: 19 August, 2018
Market Authorisation Date: 19 August, 2014
Treatment: NA
Dosage: CAPSULE;ORAL
CERDELGA family patents
41. Children's Allegra Allergy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(6 years from now) | |
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
CHILDREN'S ALLEGRA ALLERGY family patents
42. Children's Allegra Hives patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(6 years from now) | |
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
CHILDREN'S ALLEGRA HIVES family patents
43. Combivent Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
COMBIVENT RESPIMAT family patents
44. Cometriq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11091439 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US8877776 | EXELIXIS | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11091440 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US11098015 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-33) | Nov 29, 2019 |
| Orphan Drug Exclusivity(ODE) | Nov 29, 2019 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 29 November, 2012
Treatment: Method of treating medullary thyroid cancer
Dosage: CAPSULE;ORAL
COMETRIQ family patents
45. Consensi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9408837 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 31, 2021 |
Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate
Dosage: TABLET;ORAL
CONSENSI family patents
46. Contrave patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8916195 | NALPROPION | Sustained release formulation of naltrexone |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONTRAVE family patents
47. Copaxone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8232250 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| US9155776 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| US9402874 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| US8969302 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| US8399413 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 28, 2017 |
| New Indication(I-594) | Feb 27, 2012 |
Drugs and Companies using GLATIRAMER ACETATE ingredient
Market Authorisation Date: 20 December, 1996
Treatment: Method of treating ms by administering copaxone
Dosage: INJECTABLE;SUBCUTANEOUS
COPAXONE family patents
48. Copiktra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8193182 | SECURA | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-208) | Sep 24, 2025 |
| Orphan Drug Exclusivity(ODE-209) | Sep 24, 2025 |
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2023 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 24 September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: NA
Dosage: CAPSULE;ORAL
COPIKTRA family patents
49. Cotellic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7803839 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-902) | Oct 28, 2025 |
| M(M-278) | Jul 28, 2025 |
| Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
| Pediatric Exclusivity(PED) | Jan 28, 2026 |
| Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: NA
Dosage: TABLET;ORAL
COTELLIC family patents
50. Creon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9198871 | ABBVIE | Delayed release pancreatin compositions |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2014 |
| M(M-93) | Jul 29, 2019 |
| New Indication(I-625) | Apr 30, 2013 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 30 April, 2013
Market Authorisation Date: 30 April, 2009
Treatment: Treatment of exocrine pancreatic insufficiency
Dosage: CAPSULE, DELAYED RELEASE;ORAL
CREON family patents
51. Cubicin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-211) | Sep 01, 2020 |
| New Patient Population(NPP) | Mar 29, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: NA
Dosage: POWDER;INTRAVENOUS
CUBICIN family patents
52. Cubicin Rf patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-211) | Sep 01, 2020 |
| New Patient Population(NPP) | Mar 29, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: NA
Dosage: POWDER;INTRAVENOUS
CUBICIN RF family patents
53. Cycloset patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9352025 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US10688155 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US8877708 | VEROSCIENCE | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US9895422 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2012 |
Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient
Market Authorisation Date: 05 May, 2009
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherei...
Dosage: TABLET;ORAL
CYCLOSET family patents
54. Dexilant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(5 years from now) | |
|
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Healing of all grades of erosive esophagitis (ee) for up to 8 weeks
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
55. Dextenza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8563027 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
Feb, 2030
(5 years from now) | |
| US8409606 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-876) | Oct 07, 2024 |
| New Indication(I-800) | Jun 20, 2022 |
| New Product(NP) | Nov 30, 2021 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery
Dosage: INSERT;OPHTHALMIC
DEXTENZA family patents
56. Dovato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 08, 2022 |
| New Indication(I-839) | Aug 06, 2023 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: NA
Dosage: TABLET;ORAL
DOVATO family patents
57. Dsuvia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10896751 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
| US11676691 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
| US8574189 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
| US8865743 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Oct, 2030
(6 years from now) | |
| US8202535 | VERTICAL PHARMS | Small-volume oral transmucosal dosage forms |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 02, 2021 |
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of acute pain
Dosage: TABLET;SUBLINGUAL
DSUVIA family patents
58. Edarbyclor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9169238 | AZURITY | Solid pharmaceutical composition |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 20 December, 2011
Treatment: NA
Dosage: TABLET;ORAL
EDARBYCLOR family patents
59. Ella patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10772897 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(5 years from now) | |
| US9283233 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(5 years from now) | |
| US10159681 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(5 years from now) | |
| US8512745 | LAB HRA PHARMA | Ulipristal acetate tablets |
Jun, 2030
(6 years from now) | |
| US8426392 | LAB HRA PHARMA | Method for providing emergency contraception |
Jun, 2030
(6 years from now) | |
| US8962603 | LAB HRA PHARMA | Method for post coital contraception in overweight or obese female subjects using ulipristal acetate |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-271) | Jun 24, 2024 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2015 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
NCE-1 date: 13 August, 2014
Market Authorisation Date: 13 August, 2010
Treatment: A method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse; Method for contra...
Dosage: TABLET;ORAL
ELLA family patents
60. Entereg patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946262 | CUBIST PHARMS | Methods of preventing and treating gastrointestinal dysfunction |
Feb, 2030
(5 years from now) | |
| US8112290 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Oct 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 20, 2013 |
Drugs and Companies using ALVIMOPAN ingredient
NCE-1 date: 20 May, 2012
Market Authorisation Date: 20 May, 2008
Treatment: A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery; Accelerating the time to upper and l...
Dosage: CAPSULE;ORAL
ENTEREG family patents
61. Epclusa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| M(M-277) | Apr 27, 2025 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 10 June, 2021
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL; TABLET;ORAL
EPCLUSA family patents
62. Erleada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445507 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc)
Dosage: TABLET;ORAL
ERLEADA family patents
63. Esbriet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7910610 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
| US8648098 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
| US8318780 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
| US8754109 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
| US8013002 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
| US7816383 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
| US8084475 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; Discontinuing administration of a strong cyp1a2 inducer to avoid re...
Dosage: CAPSULE;ORAL; TABLET;ORAL
ESBRIET family patents
64. Eucrisa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(5 years from now) | |
|
US8168614 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-191) | Apr 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2021 |
| Pediatric Exclusivity(PED) | Sep 23, 2023 |
| New Patient Population(NPP) | Mar 23, 2023 |
Drugs and Companies using CRISABOROLE ingredient
NCE-1 date: 23 September, 2022
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL
EUCRISA family patents
65. Evomela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020363 | ACROTECH BIOPHARMA | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(6 years from now) | |
| US10864183 | ACROTECH BIOPHARMA | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(6 years from now) | |
| US10940128 | ACROTECH BIOPHARMA | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 10, 2023 |
| Orphan Drug Exclusivity(ODE-110) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma
Dosage: POWDER;INTRAVENOUS
EVOMELA family patents
66. Exem Foam Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9034300 | GISKIT | Composition and method for medical imaging of body cavities |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 07, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: 08 November, 2023
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
Dosage: FOAM;INTRAUTERINE
EXEM FOAM KIT family patents
67. Fabior patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8808716 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
| US10688071 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
| US10568859 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 11, 2015 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 11 May, 2012
Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older
Dosage: AEROSOL, FOAM;TOPICAL
FABIOR family patents
68. Fanapt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9157121 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(5 years from now) | |
| US8652776 | VANDA PHARMS INC | Prediction of QT prolongation based on SNP genotype |
Aug, 2030
(6 years from now) | |
| US8999638 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(6 years from now) | |
| US9074255 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-180) | May 26, 2019 |
| New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation...
Dosage: TABLET;ORAL
FANAPT family patents
69. Farxiga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-834) | May 05, 2023 |
| M(M-212) | Oct 20, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-157) | Mar 11, 2018 |
| New Indication(I-841) | Oct 18, 2022 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: TABLET;ORAL
FARXIGA family patents
70. Fiasp patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324157 | NOVO | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 19, 2022 |
| New Product(NP) | Sep 29, 2020 |
| M(M-247) | Oct 21, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
FIASP family patents
71. Fiasp Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324157 | NOVO | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 19, 2022 |
| New Product(NP) | Sep 29, 2020 |
| M(M-247) | Oct 21, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
FIASP FLEXTOUCH family patents
72. Filspari patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993461 | TRAVERE | Method for treating disorders associated with glomerular function |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-389) | Feb 17, 2030 |
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2028 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 17 February, 2027
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: TABLET;ORAL
FILSPARI family patents
73. Flolipid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597289 | TCG FLUENT PHARMA | Liquid oral simvastatin compositions |
Feb, 2030
(5 years from now) | |
Drugs and Companies using SIMVASTATIN ingredient
Market Authorisation Date: 21 April, 2016
Treatment: NA
Dosage: SUSPENSION;ORAL
FLOLIPID family patents
74. Fosrenol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(6 years from now) | |
| US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(6 years from now) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: POWDER;ORAL
FOSRENOL family patents
75. Fyarro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206887 | AADI | Prion free nanoparticle compositions and methods of making thereof |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 22, 2024 |
| Orphan Drug Exclusivity(ODE-386) | Nov 22, 2028 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 22 November, 2021
Treatment: NA
Dosage: POWDER;INTRAVENOUS
FYARRO family patents
76. Gemtesa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Dosage: TABLET;ORAL
GEMTESA family patents
77. Genosyl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103669 | VERO BIOTECH INC | Nitric oxide therapies |
Jun, 2030
(6 years from now) | |
| US8607785 | VERO BIOTECH INC | Systems and devices for generating nitric oxide |
Jul, 2030
(6 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: GAS;INHALATION
GENOSYL family patents
78. Genvoya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(6 years from now) | |
|
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
GENVOYA family patents
79. Giapreza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9572856 | LA JOLLA PHARMA | Method of treating low blood pressure |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 21 December, 2021
Market Authorisation Date: 23 December, 2021
Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor
Dosage: SOLUTION;INTRAVENOUS
GIAPREZA family patents
80. Gilotrif patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8426586 (Pediatric) | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Apr, 2030
(5 years from now) | |
|
US8545884 (Pediatric) | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Jun, 2030
(6 years from now) | |
| US10004743 | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-230) | Jan 12, 2025 |
| M(M-276) | Apr 07, 2025 |
| Pediatric Exclusivity(PED) | Oct 07, 2025 |
| Orphan Drug Exclusivity(ODE) | Apr 15, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 12, 2018 |
| New Indication(I-730) | Apr 15, 2019 |
| Orphan Drug Exclusivity(ODE-115) | Apr 15, 2023 |
| New Indication(I-763) | Jan 12, 2021 |
| Orphan Drug Exclusivity(ODE-50) | Jul 12, 2020 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
NCE-1 date: 07 October, 2024
Market Authorisation Date: 12 July, 2013
Treatment: NA
Dosage: TABLET;ORAL
GILOTRIF family patents
81. Gimoti patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8334281 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2023 |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 June, 2020
Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis
Dosage: SPRAY, METERED;NASAL
GIMOTI family patents
82. Glyxambi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-739) | Dec 02, 2019 |
| New Combination(NC) | Jan 30, 2018 |
| M(M-258) | Jul 03, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin
Dosage: TABLET;ORAL
GLYXAMBI family patents
83. Gocovri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9867793 | ADAMAS OPERATIONS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(6 years from now) | |
| US9867792 | ADAMAS OPERATIONS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(6 years from now) | |
| US8741343 | ADAMAS OPERATIONS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(6 years from now) | |
| US9867791 | ADAMAS OPERATIONS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(6 years from now) | |
| US11197835 | ADAMAS OPERATIONS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(6 years from now) | |
| US9877933 | ADAMAS OPERATIONS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-153) | Aug 24, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 24, 2024 |
| New Indication(I-769) | Aug 24, 2020 |
| New Product(NP) | Aug 24, 2020 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time with...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
GOCOVRI family patents
84. Harvoni patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8822430 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US8088368 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9511056 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US8841278 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US8273341 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
|
US8088368 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US8822430 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US8841278 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US9511056 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US8273341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
| ODE*(ODE*) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Dosing Schedule(D-158) | Feb 12, 2019 |
| New Dosing Schedule(D-159) | Feb 12, 2019 |
| New Dosing Schedule(D-160) | Feb 12, 2019 |
| New Patient Population(NPP) | Apr 07, 2020 |
| New Indication(I-718) | Nov 12, 2018 |
| New Dosing Schedule(D-153) | Nov 12, 2018 |
| New Indication(I-719) | Nov 12, 2018 |
| New Indication(I-720) | Nov 12, 2018 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL; PELLETS;ORAL
HARVONI family patents
85. Ibsrela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
Dosage: TABLET;ORAL
IBSRELA family patents
86. Idhifa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | BRISTOL MYERS SQUIBB | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
IDHIFA family patents
87. Idose Tr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206813 | GLAUKOS | Implants with controlled drug delivery features and methods of using same |
Oct, 2030
(6 years from now) | |
| US11426306 | GLAUKOS | Implants with controlled drug delivery features and methods of using same |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 13, 2026 |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 13 December, 2023
Treatment: NA
Dosage: IMPLANT;INTRACAMERAL
IDOSE TR family patents
88. Ilevro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9662398 | HARROW EYE | Carboxylvinyl polymer-containing nanoparticle suspensions |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 16, 2015 |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ILEVRO family patents
89. Implanon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 31, 2014 |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT;IMPLANTATION
IMPLANON family patents
90. Impoyz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9956231 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US10064875 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US10588914 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 28, 2020 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: Plaque psoriasis; Twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older
Dosage: CREAM;TOPICAL
IMPOYZ family patents
91. Incruse Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8534281 | GLAXO GRP ENGLAND | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
| US8746242 | GLAXO GRP ENGLAND | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-172) | Feb 24, 2019 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: NA
Dosage: POWDER;INHALATION
INCRUSE ELLIPTA family patents
92. Inlyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8791140 | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: TABLET;ORAL
INLYTA family patents
93. Inpefa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8217156 | LEXICON PHARMS INC | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Treatment: NA
Dosage: TABLET;ORAL
INPEFA family patents
94. Inqovi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8268800 | OTSUKA | Certain compounds, compositions and methods |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2025 |
| Orphan Drug Exclusivity(ODE-316) | Jul 07, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 07 July, 2024
Market Authorisation Date: 07 July, 2020
Treatment: Method for inhibiting degradation of a cda substrate by administering cedazuridine
Dosage: TABLET;ORAL
INQOVI family patents
95. Intrarosa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8957054 | MILLICENT | Pharmaceutical compositions |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2021 |
Drugs and Companies using PRASTERONE ingredient
NCE-1 date: 16 November, 2020
Market Authorisation Date: 16 November, 2016
Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Dosage: INSERT;VAGINAL
INTRAROSA family patents
96. Invokamet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11576894 | JANSSEN PHARMS | Combination therapy for the treatment of diabetes |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Combination(NC) | Aug 08, 2017 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 08 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
INVOKAMET family patents
97. Isentress patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 22, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
| New Dosage Form(NDF) | Dec 21, 2014 |
| M(M-114) | Mar 28, 2015 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET, CHEWABLE;ORAL; TABLET;ORAL
ISENTRESS family patents
98. Isentress Hd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649311 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 26, 2020 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| New Patient Population(NPP) | Dec 21, 2014 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
| M(M-114) | Mar 28, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
ISENTRESS HD family patents
99. Jardiance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-869) | Aug 18, 2024 |
| New Indication(I-922) | Sep 21, 2026 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-159) | Jun 26, 2018 |
| New Indication(I-739) | Dec 02, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin
Dosage: TABLET;ORAL
JARDIANCE family patents
100. Jatenzo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10617696 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778916 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US11426416 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US10543219 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US11179403 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US8492369 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: A method of treating testosterone deficiency in men; Method of treating testosterone deficiency
Dosage: CAPSULE;ORAL
JATENZO family patents
101. Jentadueto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
|
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(6 years from now) | |
|
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-146) | Jul 30, 2017 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET;ORAL
JENTADUETO family patents
102. Jentadueto Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
|
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR family patents
103. Jevtana Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
| US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
| US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-209) | Sep 14, 2020 |
| M(M-201) | May 17, 2020 |
| M(M-128) | Dec 18, 2023 |
| Pediatric Exclusivity(PED) | Nov 17, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
Drugs and Companies using CABAZITAXEL ingredient
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antih...
Dosage: SOLUTION;INTRAVENOUS
JEVTANA KIT family patents
104. Jublia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
| US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
| US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
| US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(6 years from now) | |
| US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 27, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis
Dosage: SOLUTION;TOPICAL
JUBLIA family patents
105. Juluca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
JULUCA family patents
106. Jynarque patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-178) | Apr 23, 2025 |
| New Indication(I-779) | Apr 23, 2021 |
Drugs and Companies using TOLVAPTAN ingredient
Market Authorisation Date: 23 April, 2018
Treatment: NA
Dosage: TABLET;ORAL
JYNARQUE family patents
107. Kengreal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9427448 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 22, 2020 |
Drugs and Companies using CANGRELOR ingredient
NCE-1 date: 23 June, 2019
Market Authorisation Date: 22 June, 2015
Treatment: Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/m...
Dosage: POWDER;INTRAVENOUS
KENGREAL family patents
108. Kimyrsa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER;INTRAVENOUS
KIMYRSA family patents
109. Kisqali patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 10, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Indication(I-784) | Jul 18, 2021 |
| New Indication(I-783) | Jul 18, 2021 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: NA
Dosage: TABLET;ORAL
KISQALI family patents
110. Kisqali Femara Co-pack (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 10, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: NA
Dosage: TABLET;ORAL
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
111. Kovanaze patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8580282 | ST RENATUS | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration |
Apr, 2030
(5 years from now) | |
| US9308191 | ST RENATUS | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jun 29, 2019 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 June, 2016
Treatment: Method of anesthetizing at least a portion of the maxillary dental arch
Dosage: SPRAY, METERED;NASAL
KOVANAZE family patents
112. Kybella patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10500214 | KYTHERA BIOPHARMS | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
| US8653058 | KYTHERA BIOPHARMS | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
Mar, 2030
(5 years from now) | |
| US8367649 | KYTHERA BIOPHARMS | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
| US8101593 | KYTHERA BIOPHARMS | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
KYBELLA family patents
113. Kynmobi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10420763 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9283219 | SUMITOMO PHARMA AM | Sublingual films |
Jun, 2030
(6 years from now) | |
| US9669019 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9669021 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9326981 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9044475 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL
KYNMOBI family patents
114. Kyzatrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576089 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| US11590146 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| US10576090 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE;ORAL
KYZATREX family patents
115. Lonhala Magnair Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789270 | SUMITOMO PHARMA AM | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;INHALATION
LONHALA MAGNAIR KIT family patents
116. Lumify patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(6 years from now) | |
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2020 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIFY family patents
117. Mavyret patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028937 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US10039754 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9586978 | ABBVIE | Anti-viral compounds |
Nov, 2030
(6 years from now) | |
|
US10028937 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
|
US10039754 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-232) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-233) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| M(M-259) | Apr 10, 2023 |
| M(M-230) | Aug 06, 2021 |
| New Patient Population(NPP) | Apr 30, 2022 |
| New Dosing Schedule(D-175) | Sep 26, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 03 August, 2017
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv)...
Dosage: TABLET;ORAL; PELLETS;ORAL
MAVYRET family patents
118. Mayzent patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 26, 2024 |
| M(M-274) | Mar 01, 2025 |
Drugs and Companies using SIPONIMOD ingredient
NCE-1 date: 27 March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Dosage: TABLET;ORAL
MAYZENT family patents
119. Mekinist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Product(NP) | Mar 16, 2026 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 16 March, 2023
Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; Me...
Dosage: SOLUTION;ORAL; TABLET;ORAL
MEKINIST family patents
120. Mektovi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-appr...
Dosage: TABLET;ORAL
MEKTOVI family patents
121. Milprosa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8580293 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2023 |
Drugs and Companies using PROGESTERONE ingredient
Market Authorisation Date: 29 April, 2020
Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women
Dosage: SYSTEM;VAGINAL
MILPROSA family patents
122. Minivelle patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8231906 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2030
(6 years from now) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 23 September, 2014
Treatment: NA
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
MINIVELLE family patents
123. Mulpleta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8530668 | VANCOCIN ITALIA | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 31 July, 2018
Treatment: NA
Dosage: TABLET;ORAL
MULPLETA family patents
124. Myoview 30ml patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549999 | GE HEALTHCARE | Radiopharmaceutical composition |
Mar, 2030
(5 years from now) | |
Drugs and Companies using TECHNETIUM TC-99M TETROFOSMIN KIT ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: INJECTABLE;INJECTION
MYOVIEW 30ML family patents
125. Myrbetriq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) | |
|
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
| New Indication(I-777) | Apr 27, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
MYRBETRIQ family patents
126. Nerlynx patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7399865 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Dec, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9211291 | PUMA BIOTECH | Treatment regimen utilizing neratinib for breast cancer |
Mar, 2030
(5 years from now) | |
| US8790708 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(6 years from now) | |
| US8518446 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-182) | Jun 28, 2024 |
| New Chemical Entity Exclusivity(NCE) | Jul 17, 2022 |
| New Indication(I-823) | Feb 25, 2023 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: 17 July, 2021
Market Authorisation Date: 17 July, 2017
Treatment: Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; Use in combination ...
Dosage: TABLET;ORAL
NERLYNX family patents
127. Neupro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(6 years from now) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-647) | Apr 02, 2015 |
| New Indication(I-646) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Treatment: NA
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO family patents
128. Nexplanon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 31, 2014 |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT;IMPLANTATION
NEXPLANON family patents
129. Nithiodote patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11753301 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Feb, 2030
(5 years from now) | |
| US9585912 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| US9345724 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687506 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Feb, 2030
(5 years from now) | |
| US10479686 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
| Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient
Market Authorisation Date: 14 January, 2011
Treatment: Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning; Sodium thiosulfate injection is administered by intravenous injection; Tr...
Dosage: SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS
NITHIODOTE family patents
130. Nocdurna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9974826 | FERRING PHARMS INC | Methods comprising desmopressin |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2021 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults
Dosage: TABLET;SUBLINGUAL
NOCDURNA family patents
131. Noctiva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9539302 | ACERUS PHARMS | Safe desmopressin administration |
Jun, 2030
(6 years from now) | |
| US11419914 | ACERUS PHARMS | Safe desmopressin administration |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 03, 2020 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising ...
Dosage: SPRAY, METERED;NASAL
NOCTIVA family patents
132. Nubeqa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(6 years from now) | |
| US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(6 years from now) | |
| US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET;ORAL
NUBEQA family patents
133. Nuplazid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7601740 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: NA
Dosage: CAPSULE;ORAL; TABLET;ORAL
NUPLAZID family patents
134. Nurtec Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8314117 | PFIZER | CGRP receptor antagonists |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 27, 2025 |
| New Indication(I-865) | May 27, 2024 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 28 February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT family patents
135. Nuzyra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383610 | PARATEK PHARMS INC | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: NA
Dosage: TABLET;ORAL
NUZYRA family patents
136. Ojjaara patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486941 | GLAXOSMITHKLINE | Phenyl amino pyrimidine compounds and uses thereof |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-441) | Sep 15, 2030 |
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2028 |
Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 16 September, 2027
Market Authorisation Date: 15 September, 2023
Treatment: For the treatment of intermediate or high-risk myelofibrosis
Dosage: TABLET;ORAL
OJJAARA family patents
137. Olumiant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-890) | Jun 13, 2025 |
| New Indication(I-891) | May 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Treatment: NA
Dosage: TABLET;ORAL
OLUMIANT family patents
138. Ongentys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10071085 | NEUROCRINE | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
| US10583130 | NEUROCRINE | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Method of treating parkinson's disease
Dosage: CAPSULE;ORAL
ONGENTYS family patents
139. Onpattro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802644 | ALNYLAM PHARMS INC | Lipid formulation |
Oct, 2030
(6 years from now) | |
| US8158601 | ALNYLAM PHARMS INC | Lipid formulation |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION;INTRAVENOUS
ONPATTRO family patents
140. Onureg patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846628 | BRISTOL | Oral formulations of cytidine analogs and methods of use thereof |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-320) | Sep 01, 2027 |
| New Product(NP) | Sep 01, 2023 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...
Dosage: TABLET;ORAL
ONUREG family patents
141. Onzetra Xsail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8899229 | CURRAX | Powder delivery devices |
Aug, 2030
(6 years from now) | |
| US9649456 | CURRAX | Nasal administration |
Oct, 2030
(6 years from now) | |
| US8978647 | CURRAX | Nasal delivery |
Dec, 2030
(6 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device
Dosage: POWDER;NASAL
ONZETRA XSAIL family patents
142. Orbactiv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections
Dosage: POWDER;INTRAVENOUS
ORBACTIV family patents
143. Orenitram patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410169 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Indication(I-820) | Oct 18, 2022 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
ORENITRAM family patents
144. Orkambi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8507534 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8716338 | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2030
(6 years from now) | |
| US8993600 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Sep 28, 2023 |
| Pediatric Exclusivity(PED) | Jan 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jan 02, 2028 |
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
| Orphan Drug Exclusivity(ODE-123) | Sep 28, 2023 |
| New Patient Population(NPP) | Sep 28, 2019 |
| Orphan Drug Exclusivity(ODE-93) | Jul 02, 2022 |
| M(M-218) | Jan 25, 2021 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
NCE-1 date: 02 January, 2022
Market Authorisation Date: 28 September, 2016
Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using the dosage unit comprising lumacaftor as recited in claim 1 of us patent 87163...
Dosage: TABLET;ORAL; GRANULE;ORAL
ORKAMBI family patents
145. Osmolex Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252331 | ADAMAS OPERATIONS | Osmotic device containing amantadine and an osmotic salt |
Mar, 2030
(5 years from now) | |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 2018
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
OSMOLEX ER family patents
146. Otiprio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8318817 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 10, 2018 |
| New Indication(I-770) | Mar 02, 2021 |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: Treatment of otic infection or inflammation
Dosage: INJECTABLE, SUSPENSION;OTIC
OTIPRIO family patents
147. Otovel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8932610 | LABORATORIOS SALVAT | Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 29, 2019 |
Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 April, 2016
Treatment: Treatment of acute otitis media
Dosage: SOLUTION/DROPS;OTIC
OTOVEL family patents
148. Otrexup patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497753 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US8945063 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US8480631 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US8579865 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US9421333 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 07 November, 2014
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION;SUBCUTANEOUS
OTREXUP family patents
149. Oxycontin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8894987 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
OXYCONTIN family patents
150. Parsabiv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9701712 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(6 years from now) | |
| US8377880 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(6 years from now) | |
| US9278995 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2022 |
Drugs and Companies using ETELCALCETIDE ingredient
NCE-1 date: 07 February, 2021
Market Authorisation Date: 07 February, 2017
Treatment: A method of treating secondary hyperparathyroidism (shpt)
Dosage: SOLUTION;INTRAVENOUS
PARSABIV family patents
151. Pennsaid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8546450 | HORIZON | Treatment of pain with topical diclofenac compounds |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 16, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 16 January, 2014
Treatment: Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant
Dosage: SOLUTION;TOPICAL
PENNSAID family patents
152. Pennsaid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8546450 | NUVO PHARMS INC | Treatment of pain with topical diclofenac compounds |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Nov 04, 2012 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 04 November, 2009
Treatment: Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant
Dosage: SOLUTION;TOPICAL
PENNSAID family patents
153. Phoslyra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8591938 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Feb, 2030
(5 years from now) | |
Drugs and Companies using CALCIUM ACETATE ingredient
Market Authorisation Date: 18 April, 2011
Treatment: Use of phoslyra for reduction of serum phosphorous in patients
Dosage: SOLUTION;ORAL
PHOSLYRA family patents
154. Pomalyst patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993467 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(6 years from now) | |
| US10555939 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(6 years from now) | |
|
US10555939 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(6 years from now) | |
|
US9993467 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-14) | Nov 20, 2023 |
| Orphan Drug Exclusivity(ODE-297) | May 14, 2027 |
| Orphan Drug Exclusivity(ODE-296) | May 14, 2027 |
| Pediatric Exclusivity(PED) | Nov 14, 2027 |
| New Indication(I-707) | Apr 23, 2018 |
| Orphan Drug Exclusivity(ODE-43) | Feb 08, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 08, 2020 |
| New Chemical Entity Exclusivity(NCE) | Feb 08, 2018 |
Drugs and Companies using POMALIDOMIDE ingredient
NCE-1 date: 14 November, 2026
Market Authorisation Date: 08 February, 2013
Treatment: NA
Dosage: CAPSULE;ORAL
POMALYST family patents
155. Pylarify patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8778305 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION;INTRAVENOUS
PYLARIFY family patents
156. Qbrexza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9744105 | JOURNEY | Topical glycopyrrolate formulations |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2021 |
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH;TOPICAL
QBREXZA family patents
157. Qinlock patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188113 | DECIPHERA PHARMS | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: NA
Dosage: TABLET;ORAL
QINLOCK family patents
158. Qmiiz Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8545879 | TERSERA | Fast disintegrating compositions of meloxicam |
Aug, 2030
(6 years from now) | |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 19 October, 2018
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
QMIIZ ODT family patents
159. Qternmet Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
QTERNMET XR family patents
160. Qutenza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8821920 | AVERITAS | Therapeutic patch for transdermal delivery of capsaicin |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-838) | Jul 17, 2023 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2016 |
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2014 |
Drugs and Companies using CAPSAICIN ingredient
NCE-1 date: 16 November, 2013
Market Authorisation Date: 16 November, 2009
Treatment: NA
Dosage: PATCH;TOPICAL
QUTENZA family patents
161. Quzyttir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119771 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US8513259 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US9180090 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US8263581 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US8314083 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 04, 2022 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2019
Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in...
Dosage: SOLUTION;INTRAVENOUS
QUZYTTIR family patents
162. Ravicti patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9962359 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10045958 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10183004 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US9561197 | HORIZON THERAP US | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Sep, 2030
(6 years from now) | |
| US10183006 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10668040 | HORIZON THERAP US | Treatment of urea cycle disorders in neonates and infants |
Sep, 2030
(6 years from now) | |
| US9999608 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10183002 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US8642012 | HORIZON THERAP US | Methods of treatment using ammonia-scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10183005 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10183003 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10045959 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-157) | Apr 28, 2024 |
| New Patient Population(NPP) | Dec 21, 2021 |
| Orphan Drug Exclusivity(ODE-42) | Feb 01, 2020 |
| NE(NE) | Feb 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Feb 01, 2020 |
Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder
Dosage: LIQUID;ORAL
RAVICTI family patents
163. Rayaldee patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11801253 | EIRGEN | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 17, 2019 |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: Treatment of secondary hyperparathyroidism with sustained release 25-hydroxyvitamin d in chronic kidney disease patients receiving cyp3a inhibitors
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RAYALDEE family patents
164. Relistor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247425 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION;SUBCUTANEOUS
RELISTOR family patents
165. Renvela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9095509 | GENZYME | Sachet formulation for amine polymers |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 25, 2019 |
| New Dosage Form(NDF) | Aug 12, 2012 |
Drugs and Companies using SEVELAMER CARBONATE ingredient
Market Authorisation Date: 18 February, 2009
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
RENVELA family patents
166. Rhopressa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
RHOPRESSA family patents
167. Rinvoq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47221 | ABBVIE | Tricyclic compounds |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Indication(I-919) | May 18, 2026 |
| New Indication(I-886) | Mar 16, 2025 |
| New Indication(I-888) | Apr 29, 2025 |
| New Indication(I-880) | Dec 14, 2024 |
| New Indication(I-883) | Jan 14, 2025 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
RINVOQ family patents
168. Rocklatan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
| New Combination(NC) | Mar 12, 2022 |
Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 12 March, 2019
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
ROCKLATAN family patents
169. Rydapt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-140) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-141) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)
Dosage: CAPSULE;ORAL
RYDAPT family patents
170. Safyral patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(5 years from now) | |
| US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 16, 2013 |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 16 December, 2010
Treatment: Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnancy
Dosage: TABLET;ORAL
SAFYRAL family patents
171. Salonpas patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8809615 | HISAMITSU PHARM CO | Adhesive preparation |
Jan, 2030
(5 years from now) | |
Drugs and Companies using MENTHOL; METHYL SALICYLATE ingredient
Market Authorisation Date: 20 February, 2008
Treatment: NA
Dosage: PATCH;TOPICAL
SALONPAS family patents
172. Samsca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 19, 2014 |
Drugs and Companies using TOLVAPTAN ingredient
NCE-1 date: 19 May, 2013
Market Authorisation Date: 19 May, 2009
Treatment: NA
Dosage: TABLET;ORAL
SAMSCA family patents
173. Seglentis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10245276 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| US10238668 | KOWA PHARMS | Co-crystals of tramadol and coxibis |
Apr, 2030
(5 years from now) | |
| US9012440 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| US8598152 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548909 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| US11478488 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2024 |
Drugs and Companies using CELECOXIB; TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for treatment of pain in adults using tramadol hydrochloride and celecoxib
Dosage: TABLET;ORAL
SEGLENTIS family patents
174. Segluromet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| US9439902 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
SEGLUROMET family patents
175. Sernivo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9433630 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9775851 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9877974 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9364485 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US10179137 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9655907 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9439911 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 05, 2019 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 05 February, 2016
Treatment: Treatment of plaque psoriasis
Dosage: SPRAY;TOPICAL
SERNIVO family patents
176. Silenor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8513299 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 17, 2013 |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
SILENOR family patents
177. Simbrinza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421265 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Jun, 2030
(6 years from now) | |
| US9044484 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 19, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA family patents
178. Sitavig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592434 | LNHC | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 12, 2016 |
Drugs and Companies using ACYCLOVIR ingredient
Market Authorisation Date: 12 April, 2013
Treatment: Treatment of herpes labialis
Dosage: TABLET;BUCCAL
SITAVIG family patents
179. Sivextro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10442829 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
| US9624250 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
| US8426389 | CUBIST PHARMS LLC | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10065947 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
| US9988406 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 20, 2024 |
| New Patient Population(NPP) | Jun 19, 2023 |
Drugs and Companies using TEDIZOLID PHOSPHATE ingredient
NCE-1 date: 21 June, 2023
Market Authorisation Date: 20 June, 2014
Treatment: Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria; Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS; TABLET;ORAL
SIVEXTRO family patents
180. Sodium Nitrite patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687506 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
| Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
Drugs and Companies using SODIUM NITRITE ingredient
Market Authorisation Date: 14 February, 2012
Treatment: Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning
Dosage: SOLUTION;INTRAVENOUS
SODIUM NITRITE family patents
181. Sodium Thiosulfate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11753301 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Feb, 2030
(5 years from now) | |
| US9345724 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| US9585912 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10479686 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
| Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 14 February, 2012
Treatment: Sodium thiosulfate injection is administered by intravenous injection; Sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning tha...
Dosage: SOLUTION;INTRAVENOUS
SODIUM THIOSULFATE family patents
182. Soliqua 100/33 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10029011 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
Nov, 2030
(6 years from now) | |
| US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
SOLIQUA 100/33 family patents
183. Sovaldi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
Drugs and Companies using SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL; PELLETS;ORAL
SOVALDI family patents
184. Spinraza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8361977 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing |
May, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717750 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(6 years from now) | |
| US8980853 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy; Treatment of infantile-onset spinal muscular atrophy
Dosage: SOLUTION;INTRATHECAL
SPINRAZA family patents
185. Spiriva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9010323 | BOEHRINGER INGELHEIM | Inhaler and sieve for an inhaler |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-89) | Dec 17, 2012 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 30 January, 2004
Treatment: NA
Dosage: POWDER;INHALATION
SPIRIVA family patents
186. Spiriva Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
SPIRIVA RESPIMAT family patents
187. Steglatro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLATRO family patents
188. Steglujan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| US9439901 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLUJAN family patents
189. Stiolto Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-233) | Oct 05, 2021 |
| New Combination(NC) | May 21, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
| M(M-173) | Mar 18, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 21 May, 2015
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
STIOLTO RESPIMAT family patents
190. Stivarga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680124 | BAYER HLTHCARE | Treatment of cancers with acquired resistance to kit inhibitors |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-139) | Apr 27, 2024 |
| New Indication(I-744) | Apr 27, 2020 |
| Orphan Drug Exclusivity(ODE-44) | Feb 25, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2017 |
| New Indication(I-667) | Feb 25, 2016 |
Drugs and Companies using REGORAFENIB ingredient
NCE-1 date: 27 September, 2016
Market Authorisation Date: 27 September, 2012
Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kina...
Dosage: TABLET;ORAL
STIVARGA family patents
191. Stribild patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
|
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(6 years from now) | |
|
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-704) | Dec 17, 2017 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
| New Product(NP) | Aug 27, 2015 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
STRIBILD family patents
192. Striverdi Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
STRIVERDI RESPIMAT family patents
193. Suboxone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8475832 | INDIVIOR | Sublingual and buccal film compositions |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 30, 2013 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL, SUBLINGUAL
SUBOXONE family patents
194. Subsys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8486973 | BTCP PHARMA | Sublingual fentanyl spray |
Apr, 2030
(6 years from now) | |
| US8486972 | BTCP PHARMA | Sublingual fentanyl spray |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 04, 2015 |
Drugs and Companies using FENTANYL ingredient
Market Authorisation Date: 04 January, 2012
Treatment: Treatment of pain
Dosage: SPRAY;SUBLINGUAL
SUBSYS family patents
195. Symbicort Aerosphere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
SYMBICORT AEROSPHERE family patents
196. Synjardy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610489 | BOEHRINGER INGELHEIM | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Indication(I-739) | Dec 02, 2019 |
| New Product(NP) | Aug 26, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| M(M-174) | Mar 18, 2019 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: NA
Dosage: TABLET;ORAL
SYNJARDY family patents
197. Tafinlar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7994185 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(5 years from now) | |
| US8415345 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(5 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8415345 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
|
US7994185 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-908) | Mar 16, 2026 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-170) | Nov 20, 2018 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test....
Dosage: CAPSULE;ORAL; TABLET, FOR SUSPENSION;ORAL
TAFINLAR family patents
198. Tavalisse patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263122 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Treatment: NA
Dosage: TABLET;ORAL
TAVALISSE family patents
199. Technivie patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2018 |
| New Indication(I-743) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of hcv infection using ombitasvir
Dosage: TABLET;ORAL
TECHNIVIE family patents
200. Teflaro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629861 | ABBVIE | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 13, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2015 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
NCE-1 date: 29 October, 2014
Market Authorisation Date: 29 October, 2010
Treatment: NA
Dosage: POWDER;INTRAVENOUS
TEFLARO family patents
201. Tepmetko patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2026 |
| Orphan Drug Exclusivity(ODE-325) | Feb 03, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 February, 2025
Market Authorisation Date: 03 February, 2021
Treatment: NA
Dosage: TABLET;ORAL
TEPMETKO family patents
202. Tibsovo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
| New Indication(I-893) | May 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-816) | May 02, 2022 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method for treating newly diagnosed aml with ivosidenib and azacitidine wherein the aml has an idh1 mutation capable of converting alpha-ketoglutarate to 2-hydroxyglutarate (2hg)
Dosage: TABLET;ORAL
TIBSOVO family patents
203. Tivicay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-758) | Nov 21, 2020 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| M(M-166) | Jul 30, 2018 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Treatment: NA
Dosage: TABLET;ORAL
TIVICAY family patents
204. Tivicay Pd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 June, 2020
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TIVICAY PD family patents
205. Tivorbex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734847 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
| US9089471 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
| US8992982 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 24, 2017 |
Drugs and Companies using INDOMETHACIN ingredient
Market Authorisation Date: 24 February, 2014
Treatment: Treatment of pain
Dosage: CAPSULE;ORAL
TIVORBEX family patents
206. Tlando patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11433083 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US9949985 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US10716794 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US10226473 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US11311555 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US9943527 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US11364249 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE;ORAL
TLANDO family patents
207. Tobi Podhaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10207066 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER;INHALATION
TOBI PODHALER family patents
208. Tosymra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9974770 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
| US11337962 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
| US10603305 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
| US9610280 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY;NASAL
TOSYMRA family patents
209. Tradjenta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10034877 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(5 years from now) | |
|
US9486526 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(5 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
|
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-118) | Aug 13, 2015 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET;ORAL
TRADJENTA family patents
210. Treanda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8344006 (Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(5 years from now) | |
| US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-580) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | Mar 20, 2015 |
| Pediatric Exclusivity(PED) | Sep 20, 2013 |
| ODE*(ODE*) | Dec 07, 2022 |
| New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Treatment: NA
Dosage: SOLUTION;IV (INFUSION); POWDER;IV (INFUSION)
TREANDA family patents
211. Trelegy Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol
Dosage: POWDER;INHALATION
TRELEGY ELLIPTA family patents
212. Trijardy Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(6 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Method of treating a type 2 diabetes mellitus patient with insufficient glycemic control despite therapy with metformin using a pharmaceutical composition comprising empagliflozin, linagliptin and met...
Dosage: TABLET, EXTENDED RELEASE;ORAL
TRIJARDY XR family patents
213. Triumeq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-294) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Dosing Schedule(D-147) | Mar 23, 2018 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
NCE-1 date: 15 December, 2025
Market Authorisation Date: 22 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
TRIUMEQ family patents
214. Triumeq Pd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TRIUMEQ PD family patents
215. Truqap patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8101623 | ASTRAZENECA | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...
Dosage: TABLET;ORAL
TRUQAP family patents
216. Twyneo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11071878 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(6 years from now) | |
| US10653899 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 26, 2024 |
Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient
Market Authorisation Date: 26 July, 2021
Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older
Dosage: CREAM;TOPICAL
TWYNEO family patents
217. Tybost patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-260) | Aug 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Aug 22, 2022 |
Drugs and Companies using COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
TYBOST family patents
218. Tygacil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
| New Indication(I-586) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER;INTRAVENOUS
TYGACIL family patents
219. Tyvaso Dpi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10772883 | UNITED THERAP | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: NA
Dosage: POWDER;INHALATION
TYVASO DPI family patents
220. Uptravi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Treatment: Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag
Dosage: TABLET;ORAL; POWDER;INTRAVENOUS
UPTRAVI family patents
221. Vanflyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8836218 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Mar, 2030
(5 years from now) | |
| US9555040 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
Dosage: TABLET;ORAL
VANFLYTA family patents
222. Vascepa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440650 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8357677 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8399446 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8318715 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8293728 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8431560 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8426399 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8524698 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8314086 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8377920 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8518929 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8415335 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8367652 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8546372 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8680144 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Feb, 2030
(5 years from now) | |
| US8293727 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US11103477 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8703185 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8445003 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US11717504 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Apr, 2030
(6 years from now) | |
| US8709475 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8691871 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(6 years from now) | |
| US8563608 | AMARIN PHARMS | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Apr, 2030
(6 years from now) | |
| US11213504 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8617594 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8551521 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8445013 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8623406 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8642077 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US10265287 | AMARIN PHARMS | Methods of reducing triglycerides and LDL-C |
Apr, 2030
(6 years from now) | |
| US10842766 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8618166 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(6 years from now) | |
| US8454994 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8617593 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8501225 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US11154526 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(6 years from now) | |
| US10881632 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US8298554 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US10792267 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(6 years from now) | |
| US10010517 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(6 years from now) | |
| US10842768 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(6 years from now) | |
| US8710041 | AMARIN PHARMS | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy |
Jun, 2030
(6 years from now) | |
| US8669245 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(6 years from now) | |
| US8410086 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(6 years from now) | |
| US8455472 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
| New Indication(I-819) | Dec 13, 2022 |
| New Product(NP) | Jul 26, 2015 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia; Use of vascepa to treat mixed hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 15...
Dosage: CAPSULE;ORAL
VASCEPA family patents
223. Velphoro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561251 | VIFOR FRESENIUS | Pharmaceutical compositions |
Jan, 2030
(5 years from now) | |
|
US9561251 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 27, 2016 |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: Control of phosphorous levels in patients
Dosage: TABLET, CHEWABLE;ORAL
VELPHORO family patents
224. Velsipity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580841 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Treatment: NA
Dosage: TABLET;ORAL
VELSIPITY family patents
225. Veltassa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8337824 | VIFOR PHARMA | Linear polyol stabilized polyfluoroacrylate compositions |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER;ORAL
VELTASSA family patents
226. Venclexta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174982 | ABBVIE | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy
Dosage: TABLET;ORAL
VENCLEXTA family patents
227. Vevye patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8614178 | HARROW EYE | Pharmaceutical composition for treatment of dry eye syndrome |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: NA
Dosage: SOLUTION;OPHTHALMIC
VEVYE family patents
228. Viekira Pak (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Dosing Schedule(D-163) | Apr 22, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using ombitasvir
Dosage: TABLET;ORAL
VIEKIRA PAK (COPACKAGED) family patents
229. Viekira Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using ombitasvir
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR family patents
230. Vonjo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8980873 | CTI BIOPHARMA CORP | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 28 February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2)
Dosage: CAPSULE;ORAL
VONJO family patents
231. Voquezna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
Drugs and Companies using VONOPRAZAN FUMARATE ingredient
NCE-1 date: 03 May, 2026
Market Authorisation Date: 01 November, 2023
Treatment: NA
Dosage: TABLET;ORAL
VOQUEZNA family patents
232. Voquezna Dual Pak patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | May 03, 2032 |
Drugs and Companies using AMOXICILLIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 04 May, 2031
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET;ORAL
VOQUEZNA DUAL PAK family patents
233. Voquezna Triple Pak patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | May 03, 2032 |
Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 04 May, 2031
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET, TABLET;ORAL
VOQUEZNA TRIPLE PAK family patents
234. Vosevi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor
Dosage: TABLET;ORAL
VOSEVI family patents
235. Voxzogo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 19, 2026 |
| Orphan Drug Exclusivity(ODE-449) | Oct 20, 2030 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-387) | Nov 19, 2028 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: 19 November, 2025
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
VOXZOGO family patents
236. Wakix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8207197 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2024 |
| Orphan Drug Exclusivity(ODE-255) | Aug 14, 2026 |
| Orphan Drug Exclusivity(ODE-331) | Oct 13, 2027 |
| New Indication(I-846) | Oct 13, 2023 |
Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient
NCE-1 date: 15 August, 2023
Market Authorisation Date: 14 August, 2019
Treatment: NA
Dosage: TABLET;ORAL
WAKIX family patents
237. Winlevi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785427 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: NA
Dosage: CREAM;TOPICAL
WINLEVI family patents
238. Xartemis Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8597681 | MALLINCKRODT INC | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
Dec, 2030
(6 years from now) | |
| US8980319 | MALLINCKRODT INC | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2017 |
Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
XARTEMIS XR family patents
239. Xdemvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383659 | TARSUS | Isoxazoline derivatives as pesticides |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
XDEMVY family patents
240. Xerava patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8906887 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 27, 2028 |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
NCE-1 date: 28 August, 2027
Market Authorisation Date: 27 August, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
XERAVA family patents
241. Xhance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8978647 | OPTINOSE US INC | Nasal delivery |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: SPRAY, METERED;NASAL
XHANCE family patents
242. Xigduo Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
| US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| New Indication(I-841) | Oct 18, 2022 |
| M(M-238) | Feb 22, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 28 July, 2017
Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: TABLET, EXTENDED RELEASE;ORAL
XIGDUO XR family patents
243. Xiidra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9890141 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9353088 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(6 years from now) | |
| US8927574 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
XIIDRA family patents
244. Xofluza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 23 November, 2020
Treatment: NA
Dosage: FOR SUSPENSION;ORAL; TABLET;ORAL
XOFLUZA family patents
245. Xospata patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-222) | Nov 28, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Treatment of acute myeloid leukemia (aml)
Dosage: TABLET;ORAL
XOSPATA family patents
246. Xtampza Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10004729 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
| US10668060 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
| US9682075 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2019 |
Drugs and Companies using OXYCODONE ingredient
Market Authorisation Date: 26 April, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
XTAMPZA ER family patents
247. Xtoro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993483 | FONSECA BIOSCIENCES | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(6 years from now) | |
| US9119859 | FONSECA BIOSCIENCES | Methods for treating otic infections |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
| Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
XTORO family patents
248. Xyosted (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497753 | ANTARES PHARMA INC | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
XYOSTED (AUTOINJECTOR) family patents
249. Yupelri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9765028 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| US10550081 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| US11858898 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11691948 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| US11008289 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
YUPELRI family patents
250. Zecuity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8983594 | TEVA BRANDED PHARM | Electronic control of drug delivery system |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 17, 2016 |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof
Dosage: SYSTEM;IONTOPHORESIS
ZECUITY family patents
251. Zelboraf patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741920 | HOFFMANN LA ROCHE | Process for the manufacture of pharmaceutically active compounds |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
| M(M-184) | Aug 31, 2019 |
| New Indication(I-757) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Treatment: NA
Dosage: TABLET;ORAL
ZELBORAF family patents
252. Zeposia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239846 | CELGENE INTL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2025 |
| New Indication(I-860) | May 27, 2024 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: 25 March, 2024
Market Authorisation Date: 25 March, 2020
Treatment: Indicated for the treatment of moderately to severely active ulcerative colitis
Dosage: CAPSULE;ORAL
ZEPOSIA family patents
253. Zerviate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8829005 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
| US9993471 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
| US9750684 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
|
US8829005 (Pediatric) | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 30, 2020 |
| Pediatric Exclusivity(PED) | Nov 30, 2020 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZERVIATE family patents
254. Zilxi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10322186 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10946101 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
| US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(6 years from now) | |
| US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2020
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: AEROSOL, FOAM;TOPICAL
ZILXI family patents
255. Zorvolex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679544 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
| US9186328 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
| US9180095 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
| US9180096 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
| US9173854 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
| US8999387 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
| US9017721 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-692) | Aug 22, 2017 |
| New Product(NP) | Oct 18, 2016 |
Drugs and Companies using DICLOFENAC ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treatment of pain
Dosage: CAPSULE;ORAL
ZORVOLEX family patents
256. Zubsolv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470361 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-713) | Aug 10, 2018 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2016
Treatment: Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone
Dosage: TABLET;SUBLINGUAL
ZUBSOLV family patents
257. Zuplenz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9095577 | AQUESTIVE | Stabilized amine-containing actives in oral film compositions |
Jul, 2030
(6 years from now) | |
Drugs and Companies using ONDANSETRON ingredient
Market Authorisation Date: 02 July, 2010
Treatment: NA
Dosage: FILM;ORAL
ZUPLENZ family patents
258. Zyclara patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11202752 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Apr, 2030
(6 years from now) | |
| US10918635 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2013 |
| New Indication(I-636) | Mar 24, 2014 |
| New Strength(NS) | Jul 15, 2014 |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 15 July, 2011
Treatment: Treatment of genital warts; Treatment of perianal warts
Dosage: CREAM;TOPICAL
ZYCLARA family patents
259. Zydelig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Treatment: In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll)
Dosage: TABLET;ORAL
ZYDELIG family patents
260. Zykadia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039474 | NOVARTIS | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
Jun, 2030
(6 years from now) | |
| US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-145) | May 26, 2024 |
| M(M-199) | May 26, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
| Orphan Drug Exclusivity(ODE) | May 26, 2024 |
| Orphan Drug Exclusivity(ODE-66) | Apr 29, 2021 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 29 April, 2014
Treatment: NA
Dosage: TABLET;ORAL
ZYKADIA family patents
List of large molecules
1. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8420081 | ABBVIE INC. | Antibody formulations and methods of making same |
Jan, 2030
(5 years from now) |
Ingredients: ADALIMUMAB
2. List of Taltz large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7838638 | NA | Anti-IL-17 antibodies |
Feb, 2030
(5 years from now) |
Ingredients: IXEKIZUMAB
3. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9696307 | BIOGEN INC. | Methods for the detection of JC polyoma virus |
Feb, 2030
(5 years from now) | |
| US9005926 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
Oct, 2030
(6 years from now) | |
| US9212379 | BIOGEN INC. | Nutrient monitoring and feedback control for increased bioproduct production |
Nov, 2030
(6 years from now) |
Ingredients: NATALIZUMAB
4. List of Cosentyx large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7807155 | NA | IL-17 antagonistic antibodies |
Feb, 2030
(5 years from now) |
Ingredients: SECUKINUMAB
5. List of Besponsa large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8153768 | NA | Calicheamicin derivative-carrier conjugates |
Apr, 2030
(5 years from now) |
Ingredients: INOTUZUMAB OZOGAMICIN
6. List of Tecentriq large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8217149 | NA | Anti-PD-L1 antibodies, compositions and articles of manufacture |
May, 2030
(6 years from now) |
Ingredients: ATEZOLIZUMAB
7. List of Neulasta large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9856287 | AMGEN, INC. | Refolding proteins using a chemically controlled redox state |
Jun, 2030
(6 years from now) |
Ingredients: PEGFILGRASTIM
8. List of Arzerra large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8529902 | NA | NA |
Aug, 2030
(6 years from now) |
Ingredients: OFATUMUMAB
9. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10982003 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Aug, 2030
(6 years from now) | |
| US9714293 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Aug, 2030
(6 years from now) |
Ingredients: BEVACIZUMAB